Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007787 · ClinicalTrials.gov registry record · NA
Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants
A NA study of Kidney Transplantation and Chronic Allograft Nephropathy, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 350
- Enrollment target
- 1
- Study location
NCT00007787 is a NA study of Kidney Transplantation and Chronic Allograft Nephropathy that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 350 participants, above the 257-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (36% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00007787, a NA study of Kidney Transplantation and Chronic Allograft Nephropathy, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if kidney function can be improved during transplants by giving the drug Thymoglobulin with delayed cyclosporine treatment instead of initial cyclosporine treatment. There have been improvements for patients receiving kidney transplants, yet acute rejection is still a problem. This can lead to kidney failure over time. Patients whose graft fails to function properly in the first week after transplant do not do as well after 5 years as compared to patients without early problems. This study will see if Thymoglobulin, a drug that suppresses the immune system, will improve early graft function.
Conditions Studied
Interventions
- DRUG Tacrolimus
- BIOLOGICAL Cyclosporine
- BIOLOGICAL Anti-human thymocyte globulin (rabbit)
Study Locations (1)
Maryland
- Ilene Blechman-Krom - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2000-04 |
| Est. Completion | 2004-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00007787
The ClinicalTrials.gov registry entry for NCT00007787 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 257-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (36% higher). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Transplantation appearing as the primary indexed condition, and to 3 interventions - of which Tacrolimus is the first listed.
NCT00007787 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00007787 about?
NCT00007787 is a clinical study titled "Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants". The purpose of this study is to see if kidney function can be improved during transplants by giving the drug Thymoglobulin with delayed cyclosporine treatment instead of initial cyclosporine treatment. There have been improvements for patients receiving kidney transplants, yet acute rejection is st...
What is the current status of trial NCT00007787?
This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2000-04. Estimated completion is 2004-03.
What conditions does trial NCT00007787 study?
This clinical trial studies the following conditions: Kidney Transplantation, Chronic Allograft Nephropathy.
What interventions are being tested in trial NCT00007787?
The interventions under investigation include: Tacrolimus (DRUG), Cyclosporine (BIOLOGICAL), Anti-human thymocyte globulin (rabbit) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00007787?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00007787 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Prehabilitation for Kidney Transplant Candidates
RECRUITING · NA
-
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
RECRUITING · NA
-
APOL1 Genetic Testing Program for Living Donors
ACTIVE NOT RECRUITING · NA
-
Watermelon/UBIQuinone Study
ACTIVE NOT RECRUITING · NA
-
Vitamin D Replacement After Kidney Transplant
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.